{"id":8119,"date":"2020-09-09T07:00:26","date_gmt":"2020-09-09T05:00:26","guid":{"rendered":"https:\/\/www.sequanamedical.com\/?p=8119\/"},"modified":"2022-07-07T12:24:21","modified_gmt":"2022-07-07T10:24:21","slug":"sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/","title":{"rendered":"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020"},"content":{"rendered":"<p><strong>Ghent, BELGIUM \u2013 09 september 2020 \u2013 <\/strong><strong>Sequana Medical NV (Euronext Brussels: SEQUA)<\/strong>, een vernieuwer in de behandeling van vochtophoping in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat het zal deelnemen aan twee virtuele investor events in september 2020.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>H.C. Wainwright &amp; Co 22<sup>nd<\/sup> Annual Global Investment Conference, 14-16 september 2020<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><strong>KBC Life Sciences Conference, 22-23 september 2020<\/strong><\/p>\n<p>Bedrijfspresentatie door Ian Crosbie, CEO, op <em>dinsdag 22 september 2020 om 10u00 Belgische tijd<\/em><\/p>\n<p>De presentatie zal kort na het event beschikbaar zijn op de <a href=\"\/?page_id=5536\">Investors website<\/a> van Sequana Medical.<\/p>\n<p>&nbsp;<\/p>\n<p>Om een meeting met het management van Sequana Medical op \u00e9\u00e9n van deze events aan te vragen, neem contact op met <a href=\"mailto:IR@sequanamedical.com\">IR@sequanamedical.com<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Voor meer informatie, gelieve contact op te nemen met: <\/strong><\/p>\n<p><strong>Sequana Medical<\/strong><\/p>\n<p>Lies Vanneste, Director Investor Relations<\/p>\n<p>Tel: +32 498 05 35 79<\/p>\n<p>Email: <a href=\"mailto:IR@sequanamedical.com\">IR@sequanamedical.com<\/a><\/p>\n<p><strong>Consilium Strategic Communications <\/strong><\/p>\n<p>Amber Fennell, Ashley Tapp, Melissa Gardiner<\/p>\n<p>Tel: +44 203 709 5000<\/p>\n<p>Email: <a href=\"mailto:sequanamedical@consilium-comms.com\">sequanamedical@consilium-comms.com<\/a><\/p>\n<p><strong>LifeSci Advisors<\/strong><\/p>\n<p>Chris Maggos<\/p>\n<p>Tel: +41 79 367 6254<\/p>\n<p>Email: <a href=\"mailto:chris@lifesciadvisors.com\">chris@lifesciadvisors.com<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Over Sequana Medical<\/strong><\/p>\n<p>Sequana Medical is een onderneming in medische toestellen die zich in de commerci\u00eble fase bevindt en het <strong>alfa<\/strong>pump platform ontwikkelt voor het behandelen van vochtophoping bij leveraandoeningen, maligne ascites en hartfalen waarbij diuretica niet langer effectief zijn. Vochtophoping is een snelgroeiende complicatie van gevorderde leverziekte veroorzaakt door NASH (niet-alcoholische steatohepatitis)-gerelateerde cirrose en een veel voorkomende complicatie bij hartfalen. De Amerikaanse markt voor de <strong>alfa<\/strong>pump als gevolg van NASH-gerelateerde cirrose zal naar verwachting de komende 10-20 jaar meer dan \u20ac3 miljard per jaar bedragen. De markt in hartfalen voor de <strong>alfa<\/strong>pump DSR wordt geschat op meer dan \u20ac5 miljard per jaar tegen 2026 in de VS en EU5. Beide indicaties maken gebruik van de <strong>alfa<\/strong>pump van Sequana Medical, een uniek, volledig ge\u00efmplanteerd draadloos systeem dat automatisch vocht vanuit de buik in de blaas pompt, waar het op natuurlijke wijze wordt verwijderd via urinering.<\/p>\n<p>In de VS, de belangrijkste groeimarkt van de onderneming, heeft de FDA de <strong>alfa<\/strong>pump een breakthrough device status verleend. De Noord-Amerikaanse pivotale studie (POSEIDON) in terugkerende en refractaire ascites als gevolg van levercirrose is momenteel lopende en is bedoeld om een commerci\u00eble marketingapplicatie van de <strong>alfa<\/strong>pump in de VS en Canada te ondersteunen. In Europa is de <strong>alfa<\/strong>pump CE-gemarkeerd voor het behandelen van refractaire ascites als gevolg van levercirrose en maligne ascites en is opgenomen in belangrijke klinische praktijkrichtlijnen. Tot nu toe zijn meer dan 800 <strong>alfa<\/strong>pump toestellen ge\u00efmplanteerd. Voortbouwend op haar bewezen <strong>alfa<\/strong>pump platform, ontwikkelt Sequana Medical de <strong>alfa<\/strong>pump DSR, een baanbrekende, gepatenteerde aanpak voor vochtophoping door hartfalen. Klinisch proof-of-concept werd behaald in een eerste studie bij mensen met een enkelvoudige dosis DSR en de <strong>alfa<\/strong>pump DSR studie met herhaalde doses (RED DESERT) bij pati\u00ebnten met hartfalen is momenteel lopende.<\/p>\n<p>De hoofdzetel van Sequana Medical is gevestigd in Gent, Belgi\u00eb. Meer informatie is beschikbaar op de website <a href=\"https:\/\/www.sequanamedical.com\">www.sequanamedical.com<\/a>.<\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Belangrijke Regulatory Disclaimers<\/em><\/strong><\/p>\n<p><em>Het\u00a0<strong>alfa<\/strong>pump\u00ae-systeem is momenteel niet goedgekeurd in de Verenigde Staten of Canada. In de Verenigde Staten en Canada wordt het\u00a0<strong>alfa<\/strong>pump\u00ae-systeem momenteel klinisch onderzocht (POSEIDON-studie) en wordt het bestudeerd bij volwassen pati\u00ebnten met refractaire of terugkerende ascites als gevolg van cirrose. Voor meer informatie over de POSEIDON klinische studie zie\u00a0<\/em><a href=\"http:\/\/www.poseidonstudy.com\"><em>www.poseidonstudy.com<\/em><\/a><em>. De DSR-therapie is nog in ontwikkeling en er dient te worden opgemerkt dat eventuele verklaringen met betrekking tot veiligheid en effici\u00ebntie voortkomen uit lopende preklinische en klinische onderzoeken die nog moeten worden afgerond. De DSR-therapie is momenteel niet goedgekeurd voor klinisch onderzoek in de Verenigde Staten of Canada. Er is geen verband tussen de DSR-therapie en de lopende onderzoeken met het\u00a0<strong>alfa<\/strong>pump\u00ae-systeem in Europa.<\/em><\/p>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>Toekomstgerichte verklaringen<\/em><\/strong><\/p>\n<p><em>Dit persbericht kan voorspellingen, schattingen of andere informatie bevatten die als toekomstgerichte mededelingen kunnen worden beschouwd. Dergelijke toekomstgerichte mededelingen zijn geen garantie voor toekomstige resultaten. Deze toekomstgerichte mededelingen vertegenwoordigen het huidige oordeel van Sequana Medical over wat de toekomst brengt, en zijn onderhevig aan risico&#8217;s en onzekerheden die ertoe kunnen leiden dat de werkelijke resultaten substantieel verschillen. Sequana Medical wijst uitdrukkelijk elke verplichting of verbintenis af om updates of herzieningen van toekomstgerichte mededelingen in dit persbericht vrij te geven, behalve als dit specifiek vereist wordt door de wet of regelgeving. Men mag geen onvoorwaardelijk vertrouwen stellen in toekomstgerichte mededelingen, die de meningen van Sequana Medical alleen op de datum van dit persbericht weergeven.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>Download het volledige <a href=\"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2020\/09\/Press-release_Virtual-Investor-Events_9-Sept-2020_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">persbericht<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ghent, BELGIUM \u2013 09 september 2020 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA), een vernieuwer in de behandeling van vochtophoping in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat het zal deelnemen aan twee virtuele investor events in september 2020. &nbsp; H.C. Wainwright &amp; Co 22nd Annual Global Investment Conference, 14-16 september 2020 &nbsp; [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-8119","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Ghent, BELGIUM \u2013 09 september 2020 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA), een vernieuwer in de behandeling van vochtophoping in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat het zal deelnemen aan twee virtuele investor events in september 2020. &nbsp; H.C. Wainwright &amp; Co 22nd Annual Global Investment Conference, 14-16 september 2020 &nbsp; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-09T05:00:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-07T10:24:21+00:00\" \/>\n<meta name=\"author\" content=\"Lies Vanneste\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/\"},\"author\":{\"name\":\"Lies Vanneste\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\"},\"headline\":\"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020\",\"datePublished\":\"2020-09-09T05:00:26+00:00\",\"dateModified\":\"2022-07-07T10:24:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/\"},\"wordCount\":718,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/\",\"name\":\"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2020-09-09T05:00:26+00:00\",\"dateModified\":\"2022-07-07T10:24:21+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\",\"name\":\"Lies Vanneste\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"caption\":\"Lies Vanneste\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical","og_description":"Ghent, BELGIUM \u2013 09 september 2020 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA), een vernieuwer in de behandeling van vochtophoping in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat het zal deelnemen aan twee virtuele investor events in september 2020. &nbsp; H.C. Wainwright &amp; Co 22nd Annual Global Investment Conference, 14-16 september 2020 &nbsp; [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2020-09-09T05:00:26+00:00","article_modified_time":"2022-07-07T10:24:21+00:00","author":"Lies Vanneste","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/"},"author":{"name":"Lies Vanneste","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3"},"headline":"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020","datePublished":"2020-09-09T05:00:26+00:00","dateModified":"2022-07-07T10:24:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/"},"wordCount":718,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/","name":"Sequana Medical kondigt Investor Conference Schedule aan voor september 2020 - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2020-09-09T05:00:26+00:00","dateModified":"2022-07-07T10:24:21+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-kondigt-investor-conference-schedule-aan-voor-september-2020\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3","name":"Lies Vanneste","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","caption":"Lies Vanneste"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/8119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=8119"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/8119\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=8119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=8119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=8119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}